Pacira Pharmaceuticals lets injections last longer with its DepoFoam technology. The company develops sustained-release therapies based on DepoFoam, an injectable drug delivery technology that allows both immediate and sustained release. Its two marketable products are DepoCyt for treating cancer-related neoplastic meningitis and DepoDur for the treatment of post-operative pain. Pacira's lead candidate is EXPAREL, an injectable local anesthetic. The company has two manufacturing facilities that make its Depo products. Pacira went public in early 2011 through an IPO valued at about $42 million.